 "Dr Reddy's")
Hyderabad-based Dr Reddy’s Laboratories (DRL) is aiming to be among the top-five pharma players in the domestic market by focusing on the chronic therapy segment. The US would continue to remain an important geography, but the firm says it hopes to double its revenues from China and grow revenues five-fold in Brazil in the next five years.
The firm has outlined an ambitious strategy for its next leg of growth where it says by 2027; at least 25 per cent of its products will be “first to market” generics, which means they will be affordable versions of innovator products. (see
